Ziftomenib not checked
Kura Oncology, Inc. · KO-539
FollowEvery change as it happens, and a Monday email
Trials
8 active
8 in total · 5 in the EU
What this is
- How it works
- Menin Inhibitor FDA class
- Tested for
- Acute Myeloid Leukemia (3 trials), Acute Myeloid Leukemia (AML) (2 trials), AML With Mutated NPM1 (2 trials), KMT2Ar (2 trials), NPM1 Mutation (2 trials), Advanced Malignant Neoplasm, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia and 24 more
- Main trialPhase 3
- “Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the…”In the company’s words, NCT07007312 on ClinicalTrials.gov
- Other names
- KO-539
Other drugs for Acute Myeloid Leukemia
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
Coming up7
- DecPhase 1 trial completes · ClinicalTrials.gov
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- 16 Oct 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 28 Feb 2029Phase 1 trial completes · ClinicalTrials.gov
- Jun 2029Phase 1 trial completes · ClinicalTrials.gov
- Apr 2030Phase 1 trial completes · ClinicalTrials.gov
- Nov 2031Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07929740
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2031 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | |
| Phase 2Recruiting | Mar 2027 | A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | |
| Phase 1/2Active, not recruiting | 16 Oct 2028 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | |
| Phase 1Recruiting | Dec 2026 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | |
| Phase 1Not yet recruiting | 28 Feb 2029 | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS | |
| Phase 1Recruiting | Jun 2029 | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | |
| Phase 1Recruiting | Apr 2030 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | |
| Phase 1Authorised | not given | A Phase 1 Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026